TMIC-04. A POTENT MICROGLIAL RESPONSE TO BLOCKING THE CD47-SIRPα ANTI-PHAGOCYTIC AXIS OVERCOMES DEFICIENT MACROPHAGE RECRUITMENT DURING ANTI-CD47 IMMUNOTHERAPY AGAINST GLIOBLASTOMA

Neuro-Oncology - United Kingdom
doi 10.1093/neuonc/nox168.994
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Oxford University Press (OUP)

Related search

Anticancer Effects of Anti-Cd47 Immunotherapy in Vivo

OncoImmunology
OncologyAllergyImmunology
2018English

Anti-Cd47 Agent Boosts Macrophage Activity in NHL

Cancer Discovery
Oncology
2018English

A CD47-blocking TRAIL Fusion Protein With Dual Pro-Phagocytic and Pro-Apoptotic Anticancer Activity

British Journal of Haematology
Hematology
2013English

The CD47–SIRPα Pathway in Cancer Immune Evasion and Potential Therapeutic Implications

Current Opinion in Immunology
AllergyImmunology
2012English

CD47-blocking Antibodies Restore Phagocytosis and Prevent Atherosclerosis

Nature
Multidisciplinary
2016English

The Identification of a CD47-blocking “Hotspot” and Design of a CD47/PD-L1 Dual-Specific Antibody With Limited Hemagglutination

Signal Transduction and Targeted Therapy
Cancer ResearchGenetics
2020English

Increased Lymphocyte Activation and Atherosclerosis in CD47-deficient Mice

Scientific Reports
Multidisciplinary
2019English

Preparative Immunotherapy With Anti-Ox40 and Anti-Ctla4 Improves the Response to Chemotherapy

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2014English

Intestinal Microbiota Predict Response and Toxicities During Anti-Pd-1/Anti-Ctla-4 Immunotherapy

Pathology
Forensic MedicinePathology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy